Endocrinology

Study results show improvements in body composition, intrahepatic lipids, and cardiovascular risk markers in obese men treated with growth hormone for six months compared with placebo.

According to a recent retrospective study, orlistat is not associated with hepatotoxic effects after one year of use and it contributes to weight loss in obese patients.

Phase III studies show LDMP to be safe and effective for treatment of vasomotor symptoms in menopausal women.

Results from a small study indicate patients with difficult-to-treat diabetic peripheral neuropathy (DPN) may benefit from therapy with tanezumab, a humanized monoclonal antibody against nerve growth factor.

Researchers in Taiwan report that type 2 diabetes is independently associated with increased risk of peptic ulcer bleeding.

Though the causes of acute pancreatitis are unknown in roughly a quarter of its worldwide patient population, a recent analysis published in JAMA Internal Medicine has discovered a link between increased risk of the disease and medicines containing cortisone.

The American Diabetes Association revised Standards of Medical Care for patients with diabetes include several changes in recommendations regarding testing and treatment goals.

Brief summaries of research results and other articles on the clinical characteristics, evaluation, and management of patients with hyponatremia.

Results from the RELAX-AHF show serelaxin reduces cardiovascular deaths and improves symptoms in patients with heart failure.

Results from a substudy of the PLATO trial show that patients with extensive CAD and high rates of recurrent cardiovascular events, death, and bleeding may benefit from treatment with ticagrelor.

Results from a sub-study of the Trial to Assess Chelation Therapy (TACT) that focused on quality of life issues in patients who had previously suffered a heart attack and were treated with chelation therapy reveal no improvements in these patients' quality of life.

Results from the TEMPO trial presented at Kidney Week 2012 show that treatment with tolvaptan slowed the increase in total kidney volume and the decline in kidney function in patients with Autosomal Dominant Polycystic Kidney Disease (ADPKD).

Increasing numbers of people are on kidney transplant waiting lists. However, the number of potential living donors may shrink as more Americans qualify as pre-diabetic, making them less than ideal donor candidates.

Experts at Kidney Week 2012 discuss several treatment options for hyponatremia, including fluid restriction, loop diuretics, and the use of selective vasopressin V2-receptor antagonists.

A diet rich in highly alkaline fruits and vegetables helps reduce a marker of kidney injury and preserve kidney function in patients with chronic kidney disease.

Use of peritoneal dialysis in patients with end-stage renal disease is declining due to lack of physician training and awareness, financial disincentives, and other factors. However, with proper patient and provider education, it is possible to grow a successful peritoneal dialysis program.

Consuming 200 milligrams or more of caffeine per day-roughly equivalent to two cups of coffee-can either increase or decrease a woman's estrogen level, depending on her ethnic background and the source of the caffeine, a study from the National Institutes of Health (NIH) finds.

Promising initial results from a Phase 3 trial of DiaPep277 have raised hopes that an alternative to insulin may soon be available to treat type 1 diabetes.

According to a nationwide review of data from the in-patient register, 31 of the 33 autoimmune diseases studied were associated with an increased risk of pulmonary embolism (a blood clot on the lung), including type 1 diabetes.

In honor of Diabetes Awareness Month, the ADA put together video clips of health care professionals pledging to stop diabetes.

Scientists at Stanford University have identified a pathway responsible for age-related beta cell decline.

The FDA today approved Juvisync, the first combination drug developed to treat type 2 diabetes and high cholesterol.

A recent study has found that it can be very difficult for children who suffer from both type 1 diabetes and asthma to regulate their blood sugar.

Two drugs which treat type 2 diabetes could lead to a substantially increased risk of pancreatitis and pancreatic cancer.

The FDA has approved an update of the drug label of Reclast due to new evidence showing that it may increase the risk of kidney failure.